Long-term follow-up after neoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma

2001 ◽  
Vol 12 (1) ◽  
pp. 74-76 ◽  
Author(s):  
L. Arrivé ◽  
A. Vurgait ◽  
L. Monnier-Cholley ◽  
M. Lewin ◽  
P. Balladur ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Percutaneous Ethanol Injection ◽  
Ethanol Injection ◽  
Long Term Follow Up

Percutaneous Ethanol Injection of Hyperfunctioning Thyroid Nodules: Long-Term Follow-Up in 125 Patients

2008 ◽  
Vol 190 (3) ◽  
pp. 800-808 ◽  
Author(s):  
Luciano Tarantino ◽  
Giampiero Francica ◽  
Ignazio Sordelli ◽  
Pasquale Sperlongano ◽  
Domenico Parmeggiani ◽  
...  
Keyword(s):  
Thyroid Nodules ◽  
Percutaneous Ethanol Injection ◽  
Ethanol Injection ◽  
Long Term Follow Up

Long-term Follow-up Arterial Chemoembolization Combined with Transportal Ethanol Injection Used to Treat Hepatocellular Carcinoma

1999 ◽  
Vol 10 (5) ◽  
pp. 641-647 ◽  
Author(s):  
Koichiro Yamakado ◽  
Atsuhiro Nakatsuka ◽  
Naoshi Tanaka ◽  
Kaname Matsumura ◽  
Kojiro Takase ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Ethanol Injection ◽  
Long Term Follow Up ◽  
Arterial Chemoembolization

scholarly journals Percutaneous Ethanol Sclerotherapy of Symptomatic Nodules Is Effective and Safe in Pregnant Women: A Study of 13 Patients with an Average Follow-Up of 6.8 Years

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Tamas Solymosi ◽  
Zsolt Melczer ◽  
Istvan Szabolcs ◽  
Endre V. Nagy ◽  
Miklos Goth
Keyword(s):  
Percutaneous Ethanol Injection ◽  
Short Term ◽  
Ethanol Injection ◽  
Ethanol Sclerotherapy ◽  
Increased Risk ◽  
Long Term Follow Up ◽  
Nodule Volume ◽  
Ethanol Injection Therapy

Background.Because of the increased risk of surgery, thyroid nodules causing compression signs and/or hyperthyroidism are concerning during pregnancy.Patients and Methods.Six patients with nontoxic cystic, four with nontoxic solid, and three with overt hyperthyroidism caused by toxic nodules were treated with percutaneous ethanol injection therapy (PEI). An average of 0.68 mL ethanol per 1 mL nodule volume was administered. Mean number of PEI treatments for patients was 2.9. Success was defined as the shrinkage of the nodule by more than 50% of the pretreatment volume (V0) and the normalization of TSH and FT4 levels. The average V0 was 15.3 mL. Short-term success was measured prior to labor, whereas long-term success was determined during the final follow-up (an average of 6.8 years).Results.The pressure symptoms decreased in all but one patient after PEI and did not worsen until delivery. The PEI was successful in 11 (85%) and 7 (54%) patients at short-term and long-term follow-up, respectively. Three patients underwent repeat PEI which was successful in 2 patients.Conclusions.PEI is a safe tool and seems to have good short-term results in treating selected symptomatic pregnant patients. Long-term success may require repeat PEI.

Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization

1993 ◽  
Vol 34 (1) ◽  
pp. 26-29 ◽  
Author(s):  
S. Savastano ◽  
G. P. Feltrin ◽  
D. Neri ◽  
P. da Pian ◽  
M. Chiesura-Corona ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transcatheter Arterial Embolization ◽  
Palliative Treatment ◽  
Arterial Embolization ◽  
Percutaneous Ethanol Injection ◽  
Ethanol Injection ◽  
History Of ◽  
The Mean ◽  
Hcc Recurrence

Thirty-three consecutive patients with previously untreated hepatocellular carcinoma (HCC) and 6 patients with recurrent HCC were treated with transcatheter arterial embolization (TAE). The patients were not eligible for surgical resection or percutaneous ethanol injection. TAE was performed with Lipiodol Ultra-Fluid, epidoxorubicin and Gelfoam, with a mean of 1.7 treatments per patient. CT was performed 15 days after TAE. The mean cumulative survival was 14.2 months in patients with previously untreated HCC. The survival of patients stages Okuda I and II did not differ significantly (p > 0.05); tumor size did not affect survival (p > 0.05). Two patients with recurrent HCC died 7.0 and 9.3 months after the diagnosis of tumor recurrence; the remaining 4 patients are still alive with a maximum follow-up of 22.5 months from the diagnosis of HCC recurrence. Ten complications occurred in 8 patients, and were controlled by medical therapy. Eleven patients died during the study; no death was related to TAE. The series was not randomized, but comparison with the natural history of HCC suggests that TAE is effective as palliative treatment of advanced or recurrent HCC.

Sign in / Sign up

Export Citation Format

Share Document